BioSTAR(TM) Device Achieves 90 percent Closure Rate For Atrial Septal Defect In Children
A study by Canadian physicians reported that the BioSTARTM biodegradable implant achieved comparable closure rates to the Amplatzer Septal OccluderTM (ASO) in children with atrial septal defect (ASD). The BioSTAR device displayed successful outcomes, while avoiding issues associated with implants containing metal. Results of the study, the first to compare the BioSTAR device with the ASO in children, are now available online and in the July print issue of Catheterization and Cardiovascular Interventions.
Read the full story here
-
CorMatrix Receives FDA IDE Approval To Begin Prospective, Randomized Evaluation Of New Onset Postoperative Atrial Fibrillation
Drug-coated stents could boost death rate in heart attack patients
NICE Publishes Final Draft Guidance On The Use Of Dronedarone For Treating Atrial Fibrillation
In Arthritis Patients Taking NSAIDs, NT-ProBNP Is A Predictor Of CV Risk
FDA Approves For Permanent Treatment Of Advanced Heart Failure Assist Device Pioneered By Texas Heart Institute At St. Luke’s Episcopal Hospital
